Evidence map›Paper›PMID 37704069›Full record

ArticleBone2023

Antisense oligonucleotides targeting a NOTCH3 mutation in male mice ameliorate the cortical osteopenia of lateral meningocele syndrome.

Ernesto Canalis, Magda Mocarska, Lauren Schilling, Paymaan Jafar-Nejad, Michele Carrer

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ernesto CanalisDepartment of Orthopaedic Surgery, UConn Health, Farmington, CT, USA; Department of Medicine, UConn Health, Farmington, CT, USA; UConn Musculoskeletal Institute, UConn Health, Farmington, CT, USA. Electronic address: canalis@uchc.edu.
Magda MocarskaUConn Musculoskeletal Institute, UConn Health, Farmington, CT, USA.
Lauren SchillingUConn Musculoskeletal Institute, UConn Health, Farmington, CT, USA.
Paymaan Jafar-NejadIonis Pharmaceuticals, Inc., Carlsbad, CA, USA.
Michele CarrerIonis Pharmaceuticals, Inc., Carlsbad, CA, USA.
UConn Health · USIonis Pharmaceuticals (United States) · US

Funding

The Skeleton of Lateral Meningocele SyndromeR01AR072987 · NIAMS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI CANALIS, ERNESTO · 2018 to 2023
$2.2M
Targeting the Notch3 Mutation to Cure Lehman SyndromeR61AR076747 · NIAMS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI CANALIS, ERNESTO · 2019 to 2020
$799k
Targeting the Notch3 Mutation to Cure Lehman SyndromeR33AR076747 · NIAMS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI CANALIS, ERNESTO · 2022 to 2022
$411k
NIAMS NIH HHS R01 AR072987NIAMS NIH HHS R33 AR076747NIAMS NIH HHS R61 AR076747
6 · The paper itself

Abstract

Lateral Meningocele Syndrome (LMS) is a monogenic disorder associated with NOTCH3 pathogenic variants that result in the stabilization of NOTCH3 and a gain-of-function. A mouse model (Notch3

Indexed as

Bone Diseases, MetabolicMutationOligonucleotides, AntisenseReceptor, Notch3Abnormalities, MultipleAnimalsCortical BoneMaleMeningoceleMiceMice, Inbred C57BLOsteoblastsX-Ray MicrotomographyNotch3 protein, mouseOligonucleotides, AntisenseReceptor, Notch3Antisense oligonucleotidesCortical boneGene mutationsNOTCH3Notch receptorsOsteopenia

Identifiers

PMID37704069
PMCPMC10591917
OpenAlexW4386620609

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.